Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge 
Alaska Air Q3 Outlook Misses Estimates as Higher Fuel Costs Weigh on Profit Forecast 
Cathay Pacific Sees H1 Profit Surge on Strong Travel Demand 
Australia ASIC Tightens Auditor Oversight After KPMG Leak Scandal 
Wistron Opens $700M Texas AI Factory to Build Nvidia Superchips in U.S. 
Nike Shifts China Online Sales Strategy to Boost Brand and Fight Local Rivals 
Lockheed Martin Unveils Lower-Cost Patriot ACE Interceptor to Meet Rising Air Defense Demand 
Samsung Eyes Up to $1.14 Billion Investment in AI Startup Mistral 
Wistron Opens $700M Texas AI Factory to Build Nvidia GB300 Superchips 
Oracle Stock Rises After Winning Up to $6.99 Billion U.S. Defense Software Contract 
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails 
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform 
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
Intel, AMD Seek Long-Term China Server CPU Deals as AI Demand Drives Supply Crunch 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
